Calidi Biotherapeutics, Inc. (CLDI)
| Market Cap | 7.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.22M |
| Shares Out | 48.96M |
| EPS (ttm) | -1.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 885,124 |
| Open | 0.162 |
| Previous Close | 0.160 |
| Day's Range | 0.154 - 0.168 |
| 52-Week Range | 0.144 - 13.790 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 3.25 (+1,922.4%) |
| Earnings Date | May 18, 2024 |
About CLDI
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, m... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CLDI stock is "Strong Buy." The 12-month stock price forecast is $3.25, which is an increase of 1,922.40% from the latest price.
News
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24.
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering.
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics, Inc. Announces Pricing of Public Offering.
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at AACR 2024.
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results.
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
SAN DIEGO & LOS ANGELES--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics and City of Hope Announce Funding from CIRM to Advance CLD-101 (NeuroNova) in Ovarian Cancer.
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conferen...
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board.
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Sum...
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results.
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at SITC 2023.
Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023
First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total appro...
FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it reconvened and then further adjourned, without conducting any other busine...
FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET
NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it convened and then adjourned, without conducting any other business, its vi...
Flag Stockholders: Reminder to Vote for Proposed Business Combination
RESTON, Va, Aug. 16, 2023 (GLOBE NEWSWIRE) -- irst Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, reminds FLAG stockholders that the FLAG Board of...
First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, today announced that the U.S. Securities and E...
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics, a...
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and u...
First Light Acquisition Group, Inc. Announces Approval of Extension Amendment to Certificate of Incorporation
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that its Board of Directors approved an extension of the date by which it has to c...
CORRECTION - First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC
NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- CORRECTED version from November 14, 2022 5:00 a.m. release. First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”), a special purpose acquisition company...
First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC
NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”), a special purpose acquisition company, announced today that it will transfer its listing to the N...
FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to September 13, 2022 at 10:00 am ET
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it convened and then adjourned, without conducting any other business, its v...
First Light Acquisition Group, Inc. Announces the Separate Trading of its shares of Class A Common Stock and Warrants, Commencing November 1, 2021
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (the “Company”) announced that commencing November 1, 2021, holders of the units sold in the Company's initial public of...
First Light Acquisition Group, Inc. Completes $230 Million Initial Public Offering
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (the “Company”), a blank check company formed for the purpose of entering into a combination with one or more businesse...